Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
Standard
Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. / Knippen, Stefan; Löning, Thomas; Müller, Volkmar; Schröder, Christine; Jänicke, Fritz; Milde-Langosch, Karin.
in: ANTICANCER RES, Jahrgang 29, Nr. 1, 1, 2009, S. 183-189.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
AU - Knippen, Stefan
AU - Löning, Thomas
AU - Müller, Volkmar
AU - Schröder, Christine
AU - Jänicke, Fritz
AU - Milde-Langosch, Karin
PY - 2009
Y1 - 2009
N2 - BACKGROUND: The transcription factor ATF2 is overexpressed in various tumors, but its role in breast cancer is still not understood. MATERIALS AND METHODS: In a study of mammary carcinomas, the expression of ATF2 and its phosphorylated active forms was analyzed by Western blot analysis (WB; pThr69/pThr71-ATF2, n=134) and immunohistochemistry (IHC; p-ATF2-Thr6, n=110). Results were correlated with histological and clinical data, survival data, expression of ERK1/2 and two matrix metalloproteinases. RESULTS: Patients with high ATF2 expression as detected by WB had a significantly shorter overall survival (p = 0.038). This tendency was corroborated by IHC. In contrast, high p-ATF2 expression as found by WB correlated significantly with a well-differentiated phenotype, but not with prognosis. Immunohistochemically detected p-ATF2 overexpression was even associated with prolonged survival (p = 0.047). CONCLUSION: Although high ATF2 expression is associated with a poor prognosis, our data do not point to an oncogenic role of active p-ATF2 in mammary carcinomas.
AB - BACKGROUND: The transcription factor ATF2 is overexpressed in various tumors, but its role in breast cancer is still not understood. MATERIALS AND METHODS: In a study of mammary carcinomas, the expression of ATF2 and its phosphorylated active forms was analyzed by Western blot analysis (WB; pThr69/pThr71-ATF2, n=134) and immunohistochemistry (IHC; p-ATF2-Thr6, n=110). Results were correlated with histological and clinical data, survival data, expression of ERK1/2 and two matrix metalloproteinases. RESULTS: Patients with high ATF2 expression as detected by WB had a significantly shorter overall survival (p = 0.038). This tendency was corroborated by IHC. In contrast, high p-ATF2 expression as found by WB correlated significantly with a well-differentiated phenotype, but not with prognosis. Immunohistochemically detected p-ATF2 overexpression was even associated with prolonged survival (p = 0.047). CONCLUSION: Although high ATF2 expression is associated with a poor prognosis, our data do not point to an oncogenic role of active p-ATF2 in mammary carcinomas.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 183
EP - 189
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 1
M1 - 1
ER -
